Hôpital Avicenne
Bobigny, 93000, France
Location status: Recruiting
NCT Number: NCT07396623
Mental illness is a major public health issue. It affects one in five people, represents the largest expense for health insurance (14%), is the leading cause of years lived with disability, and suicide is the main cause of death among people aged 15 to 35. Depression affects 15 to 20% of individuals at some point in their lives. Trauma-related disorders affect 4.6% of people, including 1- 2% with post-traumatic stress disorder (PTSD).
Screening for mental health problems in primary care is crucial. It enables doctors to provide early treatment, reduces the need for emergency care, and decreases both the number and duration of hospital stays. However, general practitioners and other non-mental health professionals often report lacking the time, training, and tools to conduct such screenings. Fortunately, brief and validated screening tools exist in English: The PHQ-4 (Patient Health Questionnaire-4) for anxiety and depression, and the PC-PTSD-5 (Primary Care PTSD Screen for DSM-5) for PTSD. So far, no French versions of these tools have been validated.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Bobigny, 93000, France
Location status: Recruiting
A target of 10 patients per item of the tested scales was set. The PHQ-4 includes four items and the PC-PTSD-5 includes five items, corresponding to required sample sizes of 40 and 50 patients, respectively. Although the same patient sample completes both scales, these sample sizes were combined to account for potential loss to follow-up and to optimize statistical power, resulting in a total inclusion target of 90 patients.
Descriptive analyses of sociodemographic and clinical characteristics will be conducted for all included patients. Quantitative variables will be summarized using means and standard deviations, and qualitative variables using frequencies and percentages.
To address the primary objective, convergent validity will be assessed using Pearson's correlation coefficients between scores obtained on the tested scales (PHQ-4 and PC-PTSD-5) and those obtained on their respective gold standard instruments (PHQ-9, GAD-7, and PCL-5). Convergent validity will also be examined by inclusion center through comparison of correlation coefficients across centers.
Secondary objectives will be addressed through:
All statistical tests will be two-sided and considered statistically significant at an alpha level of 0.05.
No statistical imputation methods will be used for the management of missing data.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 14 days
This scale is used for the screening of anxiety and depression. The scale will be scored.
Score ranging from 0 to 12, corresponding to four levels of psychological distress:
Time frame: 14 days
Scale assessing whether the patient has experienced unusually or particularly frightening, horrible, or traumatic events. Examples include:
Time frame: At Visit 1 (at inclusion)
The time required for the patient to complete each scale (individually) will be timed and recorded (without informing the patient in order to avoid potential stress).
Interested in participating?
Request InfoAssistance Publique - Hôpitaux de Paris
Other
Validation of the French Versions of the PHQ-4 Anxiety and Depression Scale and the PC-PTSD-5 Post-Traumatic Stress Disorder Screening Scale
Acronym: DEPSYSTAGE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06789250
Alcohol Drinking Related Problems, Alcohol Use Disorders
Linköping, Sweden
View Trial DetailsNCT06572865
Anxiety, Anxiety Disorders
Fagersta, Sweden
View Trial DetailsNCT06078124
Anxiety, Anxiety Disorders
Bogotá, Colombia
View Trial DetailsNCT05078450
Anxiety Disorders, Behavior
Ann Arbor, Michigan, United States
View Trial Details